{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:03:04Z","timestamp":1784768584589,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This preliminary study explores a dual strategy of augmenting anticancer therapy with Carboplatin-loaded solid lipid nanoparticles (SLNs) alongside antigen-specific antibodies through immunization of KB oral carcinoma cells. KB and Sp2\/01 myeloma cells were cultured and assessed for viability. Female Balb\/c mice were immunized with KB cells, resulting in significant weight gainand spleen enlargement, suggesting immune activation. Enzyme-linked immunosorbent assay (ELISA) confirmed the production of antigen-specific antibodies, as indicated by an increase in absorbance at a 1:1000 serum dilution. Splenocytes from immunized mice were fused with myeloma cells using polyethylene glycol (PEG), with optimal hybridoma generation achieved in the third trial. SLNs were formulated by the microemulsion method, which exhibited favourable physicochemical properties (particle size: 144.57\u00a0nm, PDI: 0.261, zeta potential: -32 mV). Cytotoxicity assays revealed time- and dose-dependent cytotoxic effects against oral squamous cell carcinoma (OSCC), with SLNs demonstrating greater potency compared to free Carboplatin. These findings underscore the promise of SLNs in cancer therapy and the generation of KB cell-targeting antibodies using hybridoma technology.<\/jats:p>","DOI":"10.1007\/s12672-026-05229-0","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T21:33:26Z","timestamp":1779831206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Production of monoclonal antibodies (mAbs) against oralcarcinoma &amp; its bioconjugation with solid lipid nanoparticles (SLN) for drug delivery"],"prefix":"10.1007","volume":"17","author":[{"given":"Sanskruti Shrenik","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusuma Kumari","family":"Garikapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tallapaneni","family":"Vyshnavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanth Raj","family":"Palanimuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"5229_CR1","doi-asserted-by":"crossref","unstructured":"Nethan ST, Ravi P, Gupta PC. Epidemiology of oral squamous cell carcinoma in Indian scenario. InMicrobes and oral squamous cell carcinoma: A Network spanning infection and inflammation 2022. (pp. 1\u20137). Singapore: Springer Nature Singapore.","DOI":"10.1007\/978-981-19-0592-6_1"},{"key":"5229_CR2","doi-asserted-by":"publisher","first-page":"104112","DOI":"10.1016\/j.critrevonc.2023.104112","volume":"190","author":"Q Tran","year":"2023","unstructured":"Tran Q, Maddineni S, Arnaud EH, Divi V, Megwalu UC, Topf MC, Sunwoo JB. Oral cavity cancer in young, non-smoking, and non-drinking patients: A contemporary review. Crit Rev Oncol\/Hematol. 2023;190:104112.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"9","key":"5229_CR3","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/ntr\/nty074","volume":"21","author":"S Asthana","year":"2019","unstructured":"Asthana S, Labani S, Kailash U, Sinha DN, Mehrotra R. Association of smokeless tobacco use and oral cancer: a systematic global review and meta-analysis. Nicotine Tob Res. 2019;21(9):1162\u201371.","journal-title":"Nicotine Tob Res"},{"key":"5229_CR4","doi-asserted-by":"publisher","first-page":"105375","DOI":"10.1016\/j.oraloncology.2021.105375","volume":"121","author":"A Kavarthapu","year":"2021","unstructured":"Kavarthapu A, Gurumoorthy K. Linking chronic periodontitis and oral cancer: A review. Oral Oncol. 2021;121:105375.","journal-title":"Oral Oncol"},{"issue":"1","key":"5229_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F, Cui H. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target therapy. 2020;5(1):8.","journal-title":"Signal Transduct Target therapy"},{"issue":"5","key":"5229_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40259-018-0303-4","volume":"32","author":"PG Sasikumar","year":"2018","unstructured":"Sasikumar PG, Ramachandra M. Small-molecule immune checkpoint inhibitors targeting PD-1\/PD-L1 and other emerging checkpoint pathways. BioDrugs. 2018;32(5):481\u201397.","journal-title":"BioDrugs"},{"issue":"2","key":"5229_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/jcph.591","volume":"56","author":"L Lee","year":"2016","unstructured":"Lee L, Gupta M, Sahasranaman S. Immune checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. J Clin Pharmacol. 2016;56(2):157\u201369.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"5229_CR8","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3390\/biomedicines12092158","volume":"12","author":"R Ghemrawi","year":"2024","unstructured":"Ghemrawi R, Abuamer L, Kremesh S, Hussien G, Ahmed R, Mousa W, et al. Revolutionizing cancer treatment: Recent advances in immunotherapy. Biomedicines. 2024;12(9):2158.","journal-title":"Biomedicines"},{"issue":"3","key":"5229_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9(3):34.","journal-title":"Antibodies"},{"issue":"1","key":"5229_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/bmb\/lds032","volume":"104","author":"H Modjtahedi","year":"2012","unstructured":"Modjtahedi H, Ali S, Essapen S. Therapeutic application of monoclonal antibodies in cancer: advances and challenges. Br Med Bull. 2012;104(1):41\u201359.","journal-title":"Br Med Bull"},{"key":"5229_CR11","doi-asserted-by":"crossref","unstructured":"Jefferis R. Recombinant proteins and monoclonal antibodies. Adv Glycol Biotechnol. 2017;281\u2013318.","DOI":"10.1007\/10_2017_32"},{"issue":"15","key":"5229_CR12","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/ijms21155510","volume":"21","author":"S Ponziani","year":"2020","unstructured":"Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, Iacobelli S, Sala G, Capone E, Flavell DJ, Ippoliti R. Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci. 2020;21(15):5510.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5229_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","volume":"6","author":"MT Manzari","year":"2021","unstructured":"Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021;6(4):351\u201370.","journal-title":"Nat Rev Mater"},{"issue":"5","key":"5229_CR14","first-page":"259","volume":"11","author":"AA Alsaad","year":"2020","unstructured":"Alsaad AA, Hussien AA, Gareeb MM. Solid lipid nanoparticles (SLN) as a novel drug delivery system: A theoretical review. Syst Rev Pharm. 2020;11(5):259\u201373.","journal-title":"Syst Rev Pharm"},{"issue":"5","key":"5229_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3390\/nano11051251","volume":"11","author":"L Arana","year":"2021","unstructured":"Arana L, Gallego L, Alkorta I. Incorporation of antibiotics into solid lipid nanoparticles: a promising approach to reduce antibiotic resistance emergence. Nanomaterials. 2021;11(5):1251.","journal-title":"Nanomaterials"},{"issue":"5","key":"5229_CR16","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3390\/molecules27051543","volume":"27","author":"OA Madkhali","year":"2022","unstructured":"Madkhali OA. Perspectives and prospective on solid lipid nanoparticles as drug delivery systems. Molecules. 2022;27(5):1543.","journal-title":"Molecules"},{"issue":"1","key":"5229_CR17","volume":"2015","author":"K Werengowska-Cie\u0107wierz","year":"2015","unstructured":"Werengowska-Cie\u0107wierz K, Wi\u015bniewski M, Terzyk AP, Furmaniak S. The chemistry of bioconjugation in nanoparticles-based drug delivery system. Adv Condens Matter Phys. 2015;2015(1):198175.","journal-title":"Adv Condens Matter Phys"},{"key":"5229_CR18","first-page":"1","volume":"18","author":"MS Abdelhamid","year":"2025","unstructured":"Abdelhamid MS, Wadan AH, Saad HA, El-Dakroury WA, Hageen AW, Mohammed DH, Mourad S, Mohammed OA, Abdel-Reheim MA, Doghish AS. Nanoparticle innovations in targeted cancer therapy: advancements in antibody\u2013drug conjugates. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2025;18:1\u201321.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"5229_CR19","doi-asserted-by":"crossref","unstructured":"An WF. Fluorescence-based assays. InCell-based assays for high-throughput screening: methods and protocols. 2009. (pp. 97\u2013107). Totowa, NJ: Humana.","DOI":"10.1007\/978-1-60327-545-3_7"},{"key":"5229_CR20","doi-asserted-by":"crossref","unstructured":"Li F, Vijayasankaran N, Shen A, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. InMAbs 2010. (Vol. 2, No. 5, pp. 466\u201379). Taylor & Francis.","DOI":"10.4161\/mabs.2.5.12720"},{"key":"5229_CR21","doi-asserted-by":"crossref","unstructured":"Eskinazi DP, Molinaro GA, Abemayor E, Martin SE, Zighelboim J. Monoclonal antibodies against squamous cell carcinoma. Oral Surg oral Med oral Pathol. 1985;60(4):377\u201381.","DOI":"10.1016\/0030-4220(85)90259-2"},{"issue":"1","key":"5229_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/0471142735.im0205s102","volume":"102","author":"WM Yokoyama","year":"2013","unstructured":"Yokoyama WM, Christensen M, Santos GD, Miller D, Ho J, Wu T, et al. Production of monoclonal antibodies. Curr Protoc Immunol. 2013;102(1):2\u20135.","journal-title":"Curr Protoc Immunol"},{"issue":"2","key":"5229_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF01551818","volume":"3","author":"ML Gefter","year":"1977","unstructured":"Gefter ML, Margulies DH, Scharff MD. A simple method for polyethylene glycol-promotedhybridizationofmousemyelomacells. Somat Cell Mol Genet. 1977;3(2):231\u20136.","journal-title":"Somat Cell Mol Genet"},{"key":"5229_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejpb.2016.10.010","volume":"110","author":"G Sandri","year":"2017","unstructured":"Sandri G, Motta S, Bonferoni MC, Brocca P, Rossi S, Ferrari F, et al. Chitosancoupledsolidlipidnanoparticles:tuningnanostructureandmucoadhesion. Eur J Pharm Biopharm. 2017;110:13\u20138.","journal-title":"Eur J Pharm Biopharm"},{"key":"5229_CR25","doi-asserted-by":"crossref","unstructured":"Eskiler GG, Cecener G, Dikmen G, Egeli U, Tunca B.\u00a0Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer. Eur J Pharm Sci. 2018;120:73\u201388.","DOI":"10.1016\/j.ejps.2018.04.040"},{"issue":"4\u20135","key":"5229_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ejps.2012.12.017","volume":"48","author":"HV Jagani","year":"2013","unstructured":"Jagani HV, Josyula VR, Palanimuthu VR, Hariharapura RC, Gang SS. Improvement oftherapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2throughchitosan coating. Eur J Pharm Sci. 2013;48(4\u20135):611\u20138.","journal-title":"Eur J Pharm Sci"},{"key":"5229_CR27","doi-asserted-by":"crossref","unstructured":"Ghasemi M, Liang S, Luu QM, Kempson I. The MTT assay: a method for error minimization and interpretation in measuring cytotoxicity and estimating cell viability. InCell viability assays: Methods and protocols 2023. (pp. 15\u201333). New York: Springer US.","DOI":"10.1007\/978-1-0716-3052-5_2"},{"issue":"1","key":"5229_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/CAD.0000000000001131","volume":"33","author":"MS Shakil","year":"2022","unstructured":"Shakil MS, Rana Z, Hanif M, Rosengren RJ. Key considerations when using the sulforhodamine B assay for screening novel anticancer agents. Anticancer Drugs. 2022;33(1):6\u201310.","journal-title":"Anticancer Drugs"},{"key":"5229_CR29","doi-asserted-by":"publisher","first-page":"101925","DOI":"10.1016\/j.jddst.2020.101925","volume":"60","author":"L Patr\u00f3n-Romero","year":"2020","unstructured":"Patr\u00f3n-Romero L, Luque PA, Soto-Robles CA, Nava O, Vilchis-Nestor AR, Barajas-Carrillo VW, Mart\u00ednez-Ram\u00edrez CE, M\u00e9ndez JC, Palacios JA, \u00c1vila ML, Almanza-Reyes H. Synthesis, characterization and cytotoxicity of zinc oxide nanoparticles by green synthesis method. J Drug Deliv Sci Technol. 2020;60:101925.","journal-title":"J Drug Deliv Sci Technol"},{"key":"5229_CR30","doi-asserted-by":"crossref","unstructured":"Vale C, GS R. Toxicological studies with cells. Environmental Toxicology: Non-Bacterial Toxins. 2024:135\u201370.","DOI":"10.1515\/9783111014449-005"},{"issue":"1","key":"5229_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/imr.12364","volume":"268","author":"J Cervenak","year":"2015","unstructured":"Cervenak J, Kurrle R, Kacskovics I. Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity. Immunol Rev. 2015;268(1):269\u201387.","journal-title":"Immunol Rev"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05229-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05229-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05229-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:43:51Z","timestamp":1784767431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05229-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5229"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05229-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were conducted in strict accordance with the guidelines laid down by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India. The experimental protocols involving mice were reviewed and approved by the Institutional Animal Ethics Committee (IAEC) of JSS College of Pharmacy, Ooty (JSSCP\/OT\/IAEC\/21\/2021-22). The animals used for immunization were Balb\/c mice, female, aged 6\u20138 weeks, weighing 10\u201315\u00a0g. Mice were housed and maintained under standard laboratory conditions (12-hour light\/dark cycle, temperature-controlled environment, and ad libitum access to food and water). All procedures were carried out by trained personnel, in compliance with CPCSEA and institutional guidelines, to ensure the highest standards of animal ethics and care.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1061"}}